LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
Medicenna sets out plans, milestones for 2026
Profound Medical has success at Mount Sinai Hospital
Hydreight Announces $10 Million Bought Deal Private Placement
BriaCell Therapeutics Announces Closing of US$30 million Public Offering
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
BioVaxys 1Q2026 R&D and Collaborative Activity
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO(TM)
Pharmather enters obesity market with PharmaPatch
Tempramed receives validation of payer ROI model
HealthTab(TM) to Expand Across North East London
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage
BriaCell Therapeutics Announces Pricing of $30 million Public Offering